$AMRN News

Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular Risk

Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript

Amarin (NASDAQ:AMRN) Surprises with Revenue Beat but EPS Falls Short Amid Restructuring Costs

Amarin Corp Q1 Sales $45.132M Beat $43.771M Estimate

Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia

Amarin Published Data In The European Journal Of Preventive Cardiology Showing That VASCEPA Was Associated With Fewer Hospitalizations In A REDUCE-IT Analysis

Amarin Corporation plc 2025 Q4 - Results - Earnings Call Presentation

Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript

Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025

Amarin shares are trading lower after the company reported a Q4 sales miss.

Amarin Corp Q4 2025 Earnings Call Transcript

Amarin Corp Earnings Report: Q4 Overview

Amarin Corp Q4 Adj. EPS $0.01 Beats $(0.56) Estimate, Sales $49.219M Miss $50.619M Estimate

Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Amarin Highlights 25% Drop in Heart Events and 25M+ Prescriptions for Vascepa

Amarin shares are trading higher after the company reported preliminary Q4 and FY25 revenue results.

Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

Amarin Reports $217M Revenue and $303M Cash in Preliminary Full-Year 2025 Results

How the Narrative Surrounding Amarin Is Evolving After New Data and Valuation Updates